Breaking Finance News

A statement released earlier today by Raymond James Financial Inc. about Mylan NV (NASDAQ:MYL) raises the target price to $57.00

Having a price of $38.84, Mylan NV (NASDAQ:MYL) traded 8.54% higher on the day. With the last close down -11.71% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. MYL has recorded a 50-day average of $41.27 and a two hundred day average of $44.19. Trading volume was up over the average, with 8,835,533 shares of MYL changing hands over the typical 6,264,440

In a report announced on Monday October 10, 2016 Raymond James Financial Inc. upped the price target of Mylan NV (NASDAQ:MYL) to $57.00 reporting a possible upside of 0.47%.

Performance Chart

Mylan NV (NASDAQ:MYL)

With a market cap of $0, Mylan NV has 52 week low of $35.58 and a 52 week high of $55.51 with a P/E ratio of 24.69 .

About Mylan NV (NASDAQ:MYL)

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *